{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,2]],"date-time":"2025-11-02T03:16:04Z","timestamp":1762053364364,"version":"build-2065373602"},"reference-count":26,"publisher":"MDPI AG","issue":"6","license":[{"start":{"date-parts":[[2022,5,25]],"date-time":"2022-05-25T00:00:00Z","timestamp":1653436800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Antibiotics"],"abstract":"<jats:p>Vancomycin or daptomycin is administered to hemodialysis patients infected with methicillin-resistant Staphylococcus and Enterococcus species. Although serious concerns regarding nephrotoxicity due to vancomycin have been raised, it might not be a critical issue in hemodialysis patients. Moreover, very few studies have investigated the effectiveness of vancomycin versus daptomycin in patients undergoing hemodialysis. Hence, we retrospectively evaluated the effectiveness and safety of vancomycin and daptomycin in patients undergoing hemodialysis. We investigated the following measures: mortality, clinical and microbiological effectiveness, and incidence of adverse events in hemodialysis patients who received vancomycin or daptomycin from 2014 to 2019. Moreover, we evaluated the covariates related to 30-day mortality. We found that 73 patients received vancomycin, while 34 received daptomycin for the treatment of infections due to methicillin-resistant Staphylococcus aureus, methicillin-resistant coagulase-negative Staphylococci, and Enterococcus faecium. Mortality after vancomycin treatment was significantly lower than daptomycin treatment (4.1% vs. 26.5%, p &lt; 0.01). The clinical and microbiological effectiveness as well as the safety were not significantly different between the two treatments. Although daptomycin treatment with a loading dose was associated with lower mortality, the mortality of the treatment (8.3%) did not differ significantly compared to that of the vancomycin treatment (4.1%). Therefore, our findings suggest that vancomycin remains the first-line treatment for hemodialysis patients; however, a loading dose may be beneficial for patients receiving daptomycin.<\/jats:p>","DOI":"10.3390\/antibiotics11060710","type":"journal-article","created":{"date-parts":[[2022,5,25]],"date-time":"2022-05-25T05:12:27Z","timestamp":1653455547000},"page":"710","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["A Retrospective Study on the Effectiveness and Safety of Vancomycin versus Daptomycin in Hemodialysis Patients"],"prefix":"10.3390","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5272-9560","authenticated-orcid":false,"given":"Hideo","family":"Kato","sequence":"first","affiliation":[{"name":"Department of Clinical Infectious Diseases, Aichi Medical University, Nagakute 480-1195, Japan"},{"name":"Department of Pharmacy, Mie University Hospital, Tsu 514-8507, Japan"},{"name":"Department of Clinical Pharmaceutics, Division of Clinical Medical Science, Mie University Graduate School of Medicine, Tsu 514-8507, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mao","family":"Hagihara","sequence":"additional","affiliation":[{"name":"Department of Clinical Infectious Diseases, Aichi Medical University, Nagakute 480-1195, Japan"},{"name":"Department of Molecular Epidemiology and Biomedical Sciences, Aichi Medical University Hospital, Nagakute 480-1195, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mariko","family":"Kato","sequence":"additional","affiliation":[{"name":"Department of Clinical Infectious Diseases, Aichi Medical University, Nagakute 480-1195, Japan"},{"name":"Department of Pharmacy, Mie University Hospital, Tsu 514-8507, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuka","family":"Yamagishi","sequence":"additional","affiliation":[{"name":"Department of Clinical Infectious Diseases, Aichi Medical University, Nagakute 480-1195, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3160-5136","authenticated-orcid":false,"given":"Takumi","family":"Umemura","sequence":"additional","affiliation":[{"name":"Department of Clinical Infectious Diseases, Aichi Medical University, Nagakute 480-1195, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nobuhiro","family":"Asai","sequence":"additional","affiliation":[{"name":"Department of Clinical Infectious Diseases, Aichi Medical University, Nagakute 480-1195, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9184-7175","authenticated-orcid":false,"given":"Jun","family":"Hirai","sequence":"additional","affiliation":[{"name":"Department of Clinical Infectious Diseases, Aichi Medical University, Nagakute 480-1195, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takuya","family":"Iwamoto","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Mie University Hospital, Tsu 514-8507, Japan"},{"name":"Department of Clinical Pharmaceutics, Division of Clinical Medical Science, Mie University Graduate School of Medicine, Tsu 514-8507, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroshige","family":"Mikamo","sequence":"additional","affiliation":[{"name":"Department of Clinical Infectious Diseases, Aichi Medical University, Nagakute 480-1195, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2022,5,25]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.2215\/CJN.01590309","article-title":"Staphylococcus aureus infections in hemodialysis: What a nephrologist should know","volume":"4","author":"Vandecasteele","year":"2009","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1053\/j.ajkd.2012.06.003","article-title":"Characteristics of biofilm on tunneled cuffed hemodialysis catheters in the presence and absence of clinical infection","volume":"60","author":"Ramanathan","year":"2012","journal-title":"Am. J. Kidney Dis."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/S1073-4449(96)80022-7","article-title":"Epidemiological perspective on infections in chronic dialysis patients","volume":"3","author":"Bloembergen","year":"1996","journal-title":"Adv. Ren. Replace Ther."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1046\/j.1523-1755.2001.00765.x","article-title":"Infectious complications of the hemodialysis access","volume":"60","author":"Nassar","year":"2001","journal-title":"Kidney Int."},{"key":"ref_5","first-page":"617","article-title":"Sepsis in hemodialysis patients","volume":"44","author":"Iwabuchi","year":"2011","journal-title":"Jpn. Ass. Dial. Phys."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"e18","DOI":"10.1093\/cid\/ciq146","article-title":"Clinical practice guidelines by the infectious diseases society of America for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children","volume":"52","author":"Liu","year":"2011","journal-title":"Clin. Infect. Dis."},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Gaudard, P., Saour, M., Morquin, D., David, H., Eliet, J., Villiet, M., Daures, J.P., and Colson, P. (2019). Acute kidney injury during daptomycin versus vancomycin treatment in cardiovascular critically ill patients: A propensity score matched analysis. BMC Infect. Dis., 19.","DOI":"10.1186\/s12879-019-4077-1"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1128\/AAC.47.4.1318-1323.2003","article-title":"Daptomycin pharmacokinetics and safety following administration of escalating doses once daily to healthy subjects. Antimicrob","volume":"47","author":"Dvorchik","year":"2003","journal-title":"Agents Chemother."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1086\/420818","article-title":"The safety and efficacy of daptomycin for the treatment of complicated skin and skin-structure infections","volume":"38","author":"Arbeit","year":"2004","journal-title":"Clin. Infect. Dis."},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Maraolo, A.E., Giaccone, A., Saracino, A., and Bavaro, D.F. (2021). Daptomycin versus vancomycin for the treatment of methicillin-resistant Staphylococcus aureus bloodstream infection with or without endocarditis: A systematic review and meta-analysis. Antibiotics, 10.","DOI":"10.3390\/antibiotics10081014"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1016\/j.ijantimicag.2017.12.017","article-title":"Vancomycin dosing in chronic high-flux haemodialysis: A systematic review","volume":"51","author":"Hui","year":"2018","journal-title":"Int. J. Antimicrob. Agents"},{"key":"ref_12","first-page":"693","article-title":"Vancomycin pharmacokinetics and dosing recommendations in patients undergoing hemodialysis","volume":"51","author":"Igarashi","year":"2003","journal-title":"Jpn. J. Chemother."},{"key":"ref_13","unstructured":"(2006). Cubicin (Daptomycin for Injection) [Prescribing Information], Cubist Pharmaceuticals Inc."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1056\/NEJMoa053783","article-title":"Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus","volume":"355","author":"Fowler","year":"2006","journal-title":"N. Engl. J. Med."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1186\/s13063-018-2702-8","article-title":"A randomized phase 2B trial of vancomycin versus daptomycin for the treatment of methicillin-resistant Staphylococcus aureus bacteremia due to isolates with high vancomycin minimum inhibitory concentrations\u2014Results of a prematurely terminated study","volume":"19","author":"Kalimuddin","year":"2018","journal-title":"Trials"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.clinthera.2015.09.017","article-title":"Comparative Effectiveness of Vancomycin versus Daptomycin for MRSA Bacteremia with Vancomycin MIC >1 mg\/L: A Multicenter Evaluation","volume":"38","author":"Moise","year":"2016","journal-title":"Clin. Ther."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.jiac.2016.11.010","article-title":"Clinical effectiveness of daptomycin loading dose in patients infected with Gram-positive pathogens","volume":"23","author":"Kato","year":"2017","journal-title":"J. Infect. Chmother."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1086\/600877","article-title":"Vancomycin therapeutic guidelines: A summary of consensus recommendations from the infectious diseases Society of America, the American Society of Health-System Pharmacists, and the Society of Infectious Diseases Pharmacists","volume":"49","author":"Rybak","year":"2009","journal-title":"Clin. Infect. Dis."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"2227","DOI":"10.1007\/s10096-012-1560-7","article-title":"Pharmacokinetic-pharmacodynamic evaluation of daptomycin, tigecycline, and linezolid versus vancomycin for the treatment of MRSA infections in four western European countries","volume":"31","author":"Canut","year":"2012","journal-title":"Eur. J. Clin. Microbiol. Infect. Dis."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1053\/j.ajkd.2017.05.011","article-title":"Pilot Pharmacokinetic Study of High-Dose Daptomycin in Hemodialysis Patients with Infected Medical Devices","volume":"70","author":"Diolez","year":"2017","journal-title":"Am. J. Kidney Dis."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"e17639","DOI":"10.1097\/MD.0000000000017639","article-title":"The clinical efficacy and safety of vancomycin loading dose: A systematic review and meta-analysis","volume":"98","author":"Mei","year":"2019","journal-title":"Medicine"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1159\/000481158","article-title":"Considerations about the use of a loading dose of daptomycin in neutropenic murine thigh model with methicillin-resistant Staphylococcus aureus infection","volume":"63","author":"Kato","year":"2017","journal-title":"Chemotherapy"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.jiac.2019.09.004","article-title":"Retrospective study on clinical efficacy and safety for daptomycin intermittent doses with or without loading dose in renal failure patients","volume":"26","author":"Kato","year":"2020","journal-title":"J. Infect. Chemother."},{"key":"ref_24","first-page":"493","article-title":"Safety of high-dose daptomycin in patients with severe renal impairment. Ther","volume":"14","author":"Tai","year":"2018","journal-title":"Clin. Risk Manag."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1007\/s10156-013-0599-4","article-title":"Practice guidelines for therapeutic drug monitoring of vancomycin: A consensus review of the Japanese Society of Chemotherapy and the Japanese Society of Therapeutic Drug Monitoring","volume":"19","author":"Matsumoto","year":"2013","journal-title":"J. Infect. Chemother."},{"key":"ref_26","unstructured":"Clinical Laboratory Standards Institute (2015). Clinical Laboratory Standards Institute. Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically; Approved Standard, Clinical Laboratory Standards Institute. CLSI Publication M07-A10.10th Edition."}],"container-title":["Antibiotics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2079-6382\/11\/6\/710\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T23:18:07Z","timestamp":1760138287000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2079-6382\/11\/6\/710"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,25]]},"references-count":26,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2022,6]]}},"alternative-id":["antibiotics11060710"],"URL":"https:\/\/doi.org\/10.3390\/antibiotics11060710","relation":{},"ISSN":["2079-6382"],"issn-type":[{"type":"electronic","value":"2079-6382"}],"subject":[],"published":{"date-parts":[[2022,5,25]]}}}